X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Piramal Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA PIRAMAL ENTERPRISES ASTRAZENECA PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 117.7 39.6 297.1% View Chart
P/BV x 16.8 3.3 508.9% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 ASTRAZENECA PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
PIRAMAL ENTERPRISES
Mar-17
ASTRAZENECA PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs1,2852,095 61.3%   
Low Rs6341,025 61.9%   
Sales per share (Unadj.) Rs189.6492.8 38.5%  
Earnings per share (Unadj.) Rs-0.272.6 -0.3%  
Cash flow per share (Unadj.) Rs3.894.7 4.1%  
Dividends per share (Unadj.) Rs021.00 0.0%  
Dividend yield (eoy) %01.3 0.0%  
Book value per share (Unadj.) Rs68.6862.5 8.0%  
Shares outstanding (eoy) m25.00172.56 14.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.13.2 159.9%   
Avg P/E ratio x-4,712.721.5 -21,919.0%  
P/CF ratio (eoy) x249.616.5 1,514.7%  
Price / Book Value ratio x14.01.8 772.8%  
Dividend payout %028.9 0.0%   
Avg Mkt Cap Rs m23,988269,194 8.9%   
No. of employees `0001.64.0 38.8%   
Total wages/salary Rs m1,60517,939 8.9%   
Avg. sales/employee Rs Th3,040.221,190.3 14.3%   
Avg. wages/employee Rs Th1,029.24,470.1 23.0%   
Avg. net profit/employee Rs Th-3.33,120.0 -0.1%   
INCOME DATA
Net Sales Rs m4,74085,037 5.6%  
Other income Rs m922,338 3.9%   
Total revenues Rs m4,83287,374 5.5%   
Gross profit Rs m-13034,991 -0.4%  
Depreciation Rs m1013,817 2.7%   
Interest Rs m020,310 0.0%   
Profit before tax Rs m-13913,202 -1.1%   
Minority Interest Rs m01,699 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m139-100 -139.6%   
Tax Rs m52,281 0.2%   
Profit after tax Rs m-512,520 -0.0%  
Gross profit margin %-2.741.1 -6.7%  
Effective tax rate %-3.717.3 -21.2%   
Net profit margin %-0.114.7 -0.7%  
BALANCE SHEET DATA
Current assets Rs m2,72687,590 3.1%   
Current liabilities Rs m2,435185,578 1.3%   
Net working cap to sales %6.1-115.2 -5.3%  
Current ratio x1.10.5 237.2%  
Inventory Days Days7431 237.6%  
Debtors Days Days4148 85.7%  
Net fixed assets Rs m1,035108,523 1.0%   
Share capital Rs m50345 14.5%   
"Free" reserves Rs m942148,481 0.6%   
Net worth Rs m1,716148,826 1.2%   
Long term debt Rs m0144,957 0.0%   
Total assets Rs m4,156482,394 0.9%  
Interest coverage xNM1.7-  
Debt to equity ratio x01.0 0.0%  
Sales to assets ratio x1.10.2 647.0%   
Return on assets %-0.16.8 -1.8%  
Return on equity %-0.38.4 -3.5%  
Return on capital %012.0 0.0%  
Exports to sales %5.70-   
Imports to sales %6.50-   
Exports (fob) Rs m270NA-   
Imports (cif) Rs m306NA-   
Fx inflow Rs m37515,001 2.5%   
Fx outflow Rs m4705,150 9.1%   
Net fx Rs m-969,851 -1.0%   
CASH FLOW
From Operations Rs m-8-100,393 0.0%  
From Investments Rs m-146-24,202 0.6%  
From Financial Activity Rs m862135,705 0.6%  
Net Cashflow Rs m70911,110 6.4%  

Share Holding

Indian Promoters % 0.0 52.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 4.0 7.5%  
FIIs % 15.7 26.6 59.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 16.5 55.2%  
Shareholders   12,856 93,274 13.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   DIVIS LABORATORIES  WOCKHARDT LTD.  VENUS REMEDIES  PLETHICO PHARMA  GLENMARK PHARMA  

Compare ASTRAZENECA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Above 35,000 Mark; Bank & IT Stocks Outperform(Closing)

After opening the day flat, share markets in India witnessed positive trading activity throughout the day and ended the day on a strong note.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jan 17, 2018 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - GSK PHARMA COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS